Please assess the completion status of the following clinical trial:

Trial Title: Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Documented HIV infection~* Subjects must have taken HAART 6 months prior to study entry and must be on stable HAART (no dose change to antiretroviral medications) for at least 30 days immediately prior to study entry~* HDL \< 40 mg/dL • LDL \< 130 mg/dL~* All subjects with reproductive potential should utilize adequate contraception for the duration of this study and for at least 12 weeks following permanent discontinuation of study treatment. Acceptable methods include male condom, female condom, diaphragm, or intra-uterine device (IUD)~Exclusion Criteria:~* Known cardiac disease~* Arrhythmia~* History of angina~* Uncontrolled hypertension~* Pregnancy~* Breast-feeding~* Medication known to influence vasodilatation such as nitrates, metformin, pioglitazone, and rosiglitazone~* Heavy use of vitamin supplements~* Diagnosis of diabetes mellitus~* Treatment with lipid-lowering drugs within 6 weeks prior to study~* Hemoglobin \<9.0 mg/dL~* Absolute neutrophil count \<750 cells/mm3~* Platelet count \<75,000 platelets/ mm3~* Alanine aminotransferase (ALT or SGOT)/ aspartate aminotransferase (AST or SGPT) / alkaline phosphatase \> 2.5 x upper limit of normal (ULN)~* Creatinine \>1.5 x ULN~* Individuals with an infection or other medical illness requiring hospitalization within 14 days prior to study entry~* Individuals who have active alcohol or drug abuse which, in the investigator's opinion, is sufficient to prevent adequate compliance with study therapy and evaluations~* Prior history of hypersensitivity reaction to niacin or any other component of the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active Drug (extended release niacin) (Type: EXPERIMENTAL): Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
- Observation (Type: NO_INTERVENTION): Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin

Based on this trial design, predict the completion outcome and termination type (if applicable).